Molecular templates, inc. (MTEM)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11
Cash flows from operating activities:
Net loss

-85,271

-69,421

-60,174

-27,199

-27,741

-30,287

-30,568

-36,291

-30,659

-23,140

-18,789

-1,570

-4,371

-11,028

61,249

48,566

47,124

43,822

-31,855

-33,169

-25,629

-21,584

-23,209

-14,288

-26,310

-28,415

7,562

5,395

35,184

-71,135

-104,798

-107,932

-132,856

-25,653

0

0

0

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation

-

-

-

-

-

-

-

-

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Depreciation and amortization

-

-

-

-

-

-

-

-

-

-

-

-

-

-

297

804

948

1,002

1,028

1,086

1,158

1,309

1,446

1,568

1,580

1,506

1,434

1,341

1,301

1,008

0

0

0

-

-

-

-

Depreciation, amortization and other

1,623

1,182

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Stock-based compensation expense

6,691

5,859

5,560

5,230

4,709

3,992

3,124

3,305

2,409

1,792

1,454

-1,484

-708

109

2,094

5,130

6,223

6,801

6,348

6,070

5,643

5,488

5,298

5,331

5,135

4,922

4,479

4,192

3,665

3,010

2,383

1,730

1,188

1,039

0

0

0

Amortization of debt discount and accretion related to debt

529

486

446

412

360

318

279

199

367

342

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in common stock warrant fair value

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in common stock warrant fair value

-

-

-

-

-

951

1,313

1,037

745

128

-268

632

-369

3

17,434

17,121

18,675

16,773

904

248

6,355

9,344

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Accretion of asset retirement obligations

93

72

59

46

42

39

28

18

8

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss on extinguishment of debt

-

-

-

-

-

-115

-15

-4,734

-4,734

-4,619

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss on disposal of equipment

0

-

-

0

0

-

-

0

0

-

-

-56

4

-5

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in common stock warrant value

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

0

0

0

-

-

-

-

Changes in operating assets and liabilities:
Prepaid expenses

1,722

74

-195

603

528

825

1,246

619

476

410

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accounts receivable, related party

1,005

168

-31,163

-663

-3,705

240

31,125

-837

3,250

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Grants revenue receivable

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other current assets

-

-

-

-

-

-

-

-

83

12

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other assets

-345

286

439

1,093

788

450

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Operating lease right-of-use assets and liabilities

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Collaboration receivable/payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Collaboration receivable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Collaboration receivable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Collaboration receivable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

0

0

0

-

-

-

-

Change in common stock warrant value

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Prepaid expenses and other assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-450

-1,304

-381

774

67

-1,240

-43

-1,314

169

1,032

249

1,079

669

261

395

623

1,030

1,341

594

369

0

0

0

Accounts payable

110

652

-306

1,061

-579

-1,736

-2,315

-994

993

1,209

3,201

-1,526

-420

557

263

2,441

-246

-1,349

-2,978

-2,256

-2,197

385

2,039

2,007

1,652

781

636

-111

1,047

-1,481

434

517

703

2,137

0

0

0

Accrued clinical and development expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-5,623

-4,923

836

1,756

547

2,756

-1,446

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Accrued clinical and development expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

2,984

1,124

2,006

2,026

0

0

0

Accrued liabilities

2,000

6,534

1,595

637

3,179

2,667

4,891

1,815

-208

155

-779

4,921

3,855

800

643

-1,835

-3,509

89

505

-60

234

19

208

470

872

904

672

604

1,074

520

196

122

685

914

0

0

0

Other current liabilities

-

-

-

-

-

-

-

-

54

20

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other liabilities

1,914

-36

9

-335

-178

224

533

507

516

318

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other liabilities, related party

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenue

6,308

7,775

-20,208

10,567

22,551

26,136

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenue, related party

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred rent

-

-

-

-

-

-

-

-

-

-

-

-

-

-

22

82

116

112

107

105

62

-3

-10

-17

-24

28

23

17

-1

-115

0

0

0

-

-

-

-

Deferred rent

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Deferred revenue

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-76,916

-14,721

-14,722

-14,722

-14,722

-1,754

-1,254

-754

30,005

28,696

30,080

31,463

61,633

0

0

0

-

-

-

-

Net cash used in operating activities

-32,417

-25,244

-19,878

-13,207

-6,458

-4,465

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

20,183

16,092

-5,538

-23,851

0

0

0

Cash flows from investing activities:
Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-1,055

-9,028

-15,773

-33,296

-44,789

-38,003

-40,553

-40,990

-35,935

-27,735

-27,218

-23,482

-18,974

10,151

0

0

0

-

-

-

-

-

-

-

-

Purchases of property and equipment

9,962

9,649

6,630

2,653

4,628

5,722

6,153

5,271

2,812

1,101

0

0

0

-

-

-

-

109

121

108

238

224

264

232

168

158

260

351

462

482

0

0

0

-

-

-

-

Issuance of promissory notes to Molecular Templates, Inc.

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Purchases of marketable securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

30,768

31,389

56,793

48,258

51,253

55,461

44,911

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from sale of property and equipment

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Purchase of marketable securities

104,034

90,159

83,981

65,882

46,811

10,223

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

77,161

67,503

40,350

28,154

0

0

0

Increase in other assets

-

-

-

-

-

-

-

-

-

400

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Sales of marketable securities

77,241

60,084

48,583

10,893

1,293

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Net cash used in investing activities

-36,755

-39,724

-42,028

-57,642

-50,146

-15,945

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-39,071

-38,492

-16,205

-9,182

0

0

0

Cash flows from financing activities:
Proceeds from sales of marketable securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,997

3,347

8,367

13,472

14,584

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from maturities of marketable securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

65,508

66,015

65,223

58,797

54,430

58,793

53,878

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from maturities of marketable securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

0

0

0

-

-

-

-

Net cash used in investing activities

-

-

-

-

-

-

-

-

-

-

-

-

-13,121

-689

3,022

34,747

34,555

10,318

13,765

11,436

16,566

23,327

29,226

23,611

2,800

-16,293

0

0

0

-

-

-

-

-

-

-

-

Payments of capital lease obligations

-

-

-

-

-

-

-

-

45

43

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from issuance of long-term debt and warrants, net

-

-

-

-

-

4,537

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Repayment of long-term debt

200

0

0

0

0

3,605

4,205

4,805

5,405

2,400

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from issuance of related party debt

-

-

-

-

-

-

-

-

-

2,685

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from stock option exercises

2,010

1,748

1,426

974

173

283

204

217

209

61

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Principal payments on finance leases

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from promissory note

-

-

-

-

-

-

-

-

-

4,000

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from issuance of common stock and warrants, net of offering expenses

0

-

-

-

0

-

-

-

-

-

-

-

-

0

39

382

382

28,883

29,257

33,660

33,689

5,520

5,231

1,921

2,562

2,392

2,733

3,202

4,858

21,910

21,446

20,110

17,759

30,224

0

0

0

Net cash provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

-

11,249

7,188

6,018

382

382

28,883

29,257

33,660

33,689

5,520

5,231

1,921

2,562

2,392

0

0

0

-

-

-

-

-

-

-

-

Net cash provided by financing activities

65,761

65,698

1,430

48,997

48,184

49,221

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

21,446

20,110

17,759

30,224

0

0

0

Net (decrease) increase in cash, cash equivalents, and restricted cash

-3,411

730

-60,476

-21,852

-8,420

28,811

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Reconciliation of cash, cash equivalents and restricted cash
Net increase in cash and cash equivalents

-

-

-

-

-

-

-

-

-

57,194

66,549

-2,450

-2,927

-2,529

-6,733

1,833

-9,852

1,198

2,469

4,106

14,320

1,112

7,239

2,050

-13,612

-3,750

-4,633

-3,894

-5,580

5,147

2,558

-2,290

-3,984

-2,809

0

0

0

Supplemental Cash Flow Information
Cash paid for interest

673

684

857

689

752

629

342

400

233

250

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Non-Cash Investing and Financing Activities
Fixed asset additions in accounts payable and accrued expenses

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Right-of-use asset obtained in exchange for operating lease obligations

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Adoption of ASC 842

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total non-cash investing and financing activities

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deemed dividends on preferred stock

-

-

-

-

-

-

-

-

-

958

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in unrealized gain (loss) in marketable securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

4

-2

0

0

0